Advertisement

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai and David M. Weinstock

Article Information

Citation 
vol. 133 no. 6 566-575
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted July 27, 2018
  • Accepted November 26, 2018
  • Published online February 7, 2019.

Article Versions


Contributors 
  • Raphael Koch, 1Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany;
  • Amanda L. Christie, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 3Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA;
  • Jennifer L. Crombie, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Adam C. Palmer, 4Harvard Medical School, Boston, MA;
  • Deborah Plana, 4Harvard Medical School, Boston, MA;
  • Kay Shigemori, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Sara N. Morrow, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Alexandria Van Scoyk, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Wenchao Wu, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Elizabeth A. Brem, 5Division of Hematology & Oncology, Chao Family Comprehensive Center Center, UC Irvine Health, Orange, CA;
  • J. Paul Secrist, 6LifeMine Therapeutics, Cambridge, MA; and
  • Lisa Drew, 3Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA;
  • Alwin G. Schuller, 3Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA;
  • Justin Cidado, 3Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA;
  • Anthony Letai, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • David M. Weinstock, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Harvard Medical School, Boston, MA; 7Broad Institute of Harvard and MIT, Cambridge, MA

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output